多替拉韦联合拉米夫定作为一线抗逆转录病毒治疗对HIV-1储存库及外周血炎症标志物的影响
DUALITY试验为48周单中心随机开放标签临床研究,将44例初治HIV感染者按1:1随机分为多替拉韦+拉米夫定组和多替拉韦+恩曲他滨/丙酚替诺福韦组,比较两组HIV-1储存库参数和免疫激活标志物变化。第48周时除2DR组1例经梅毒治疗后重新抑制外,所有参与者血浆病毒载量均<50拷贝/mL,两组储存库参数和免疫标志物较基线变化相当。
要点
- 第48周时两组病毒载量均<50拷贝/mL,仅2DR组1例经梅毒治疗后重新抑制。
- 两组HIV-1储存库参数和免疫标志物较基线变化相当。
- 多替拉韦+拉米夫定可作为HIV感染者首选一线方案之一。
核心结论
- 多替拉韦联合拉米夫定一线治疗对HIV-1持续存在参数和免疫标志物的降低作用与多替拉韦联合恩曲他滨/丙酚替诺福韦相似,支持多替拉韦/拉米夫定作为HIV感染者首选一线抗逆转录病毒治疗方案之一。
研究设计与样本
- DUALITY为48周、单中心、随机、开放标签临床试验。
- 纳入初治HIV感染者44例,按1:1随机分为多替拉韦+拉米夫定组(2DR组)和多替拉韦+恩曲他滨/丙酚替诺福韦组(3DR组),每组22例。
主要发现
- 基线平均(标准差)log10血浆病毒载量为4.4(0.7)拷贝/mL,CD4+ T细胞计数为493(221)细胞/μL。
- 第48周时除2DR组1例经梅毒治疗后重新抑制外,所有参与者血浆病毒载量均<50拷贝/mL。
- 两组HIV-1储存库参数和免疫生物标志物较基线的变化相当。
临床怎么用
- 原文结论支持多替拉韦/拉米夫定作为HIV感染者首选一线抗逆转录病毒治疗方案之一。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare the effects of first-line antiretroviral therapy (ART) with dolutegravir plus lamivudine (DTG + 3TC) versus dolutegravir plus emtricitabine/tenofovir alafenamide (DTG + FTC/TAF) on the human immunodeficiency virus type 1 (HIV-1) reservoir and immune activation biomarkers in people with HIV (PWH). METHODS: DUALITY was a 48-week, single-center, randomized, open-label clinical trial in ART-naive PWH, randomized (1:1) to receive ART with DTG + 3TC (2DR group) or DTG + FTC/TAF (3DR group). We measured total and intact proviral HIV-1 DNA, cell-associated RNA in CD4+ T cells, frequency of HIV-infected CD4+ T cells able to produce p24, plasma soluble inflammatory markers, and activation and exhaustion markers in CD4+ and CD8+ T cells. RESULTS: Forty-four participants (22 per study arm) were enrolled, with baseline mean (standard deviation) log10 plasma viral load (pVL) 4.4 (0.7) copies/mL and CD4+ T-cell counts of 493 (221) cells/μL. At week 48, all participants had pVL <50 copies/mL at week 48, except for 1 participant in the 2DR group who was resuppressed after treating syphilis. Changes from baseline in reservoir parameters and immune biomarkers were comparable between groups. CONCLUSIONS: First-line ART with DTG + 3TC showed similar reductions of HIV-1 persistence parameters and immune markers as DTG + FTC/TAF, supporting DTG/3TC among preferred first-line ART options for PWH.
引用
- Bailón L, Puertas MC, García-Guerrero MC, et al. Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. J Infect Dis. 2025. PMID: 39465671. doi:10.1093/infdis/jiae530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。